In the adult literature, trastuzumab, an anti-human epidermal growth factor receptor 2 (HER2) monoclonal antibody used for the treatment of HER2 positive breast cancer, is widely known to contribute to cardiotoxicity [12,21,58,59]. This evidence concerns the gene ERBB2 and breast carcinoma.